Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla" today announced a significant expansion of ...

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

Cipla Q1 FY26 Results Preview, Pharma Stock Price vs Nifty 50: Cipla shares are trading with cautious gains with investors awaiting the Mumbai-headquartered pharma company's results due later in the ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The company expects continued growth from respiratory product launches and emerging ...

Cipla , India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs.

Cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in ...

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the current Good ...

CIPLA Ltd. Annual stock financials by MarketWatch. View the latest CIPLA financial statements, income statements and financial ratios.

The sale of a stake in Cipla Ltd. is in jeopardy as potential buyers have balked at the 1.09 trillion rupee ($13.1 billion) valuation members of the founding family are targeting for the Indian ...

India's Cipla (CIPL.NS) said on Saturday that its manufacturing of the COVID-19 remdesivir drug was beginning to catch up with demand after the company sought to boost production amid a massive ...